An investigation for investors in Incyte Corporation (NASDAQ:INCY) shares over potential securities laws violations by Incyte Corporation was announced and NASDAQ:INCY stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 04/30/2018 -- An investigation was announced concerning potential securities laws violations by Incyte Corporation and certain of its directors and officers in connection certain financial statements.
Investors who purchased shares of Incyte Corporation (NASDAQ:INCY), have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Incyte Corporation (NASDAQ:INCY) concerning whether certain statements by Incyte Corporation regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On April 14, 2017, Incyte Corporation revealed that the U.S. Food and Drug Administration ("FDA") had rejected the new drug application for baricitinib, a once-daily rheumatoid arthritis treatment developed in collaboration with Eli Lilly and Company. Incyte Corporation informed investors that the FDA asked for additional data to "characterize safety concerns across treatment arms" and to determine "the most appropriate doses."
On April 19, 2018, the U.S. Food and Drug Administration ("FDA") issued a briefing document in advance of the April 23, 2018 meeting of the FDA's Arthritis Advisory Committee, stating, in part, that Incyte's rheumatoid arthritis drug, baricitinib, poses serious risks of deadly blood clots at higher doses. Incyte Corporation (NASDAQ:INCY) declined from $150.42 per share in March 2017 to as low as $61.61 per share on April 26, 2018.
Those who purchased shares of Incyte Corporation (NASDAQ:INCY) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels